全球藥物遺傳學技術市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計藥物基因體學技術市場將從 2025 年的 87.7 億美元成長到 2034 年的 184.5 億美元，2026 年至 2034 年的複合年成長率為 8.62%。

隨著個人化醫療成為現代醫療保健策略的核心，全球藥物基因組學技術市場正經歷快速成長。隨著人們對藥物反應中遺傳變異性的認知不斷提高，醫療保健系統正日益將基因組檢測納入常規治療通訊協定。定序技術和生物資訊學工具的進步降低了檢測成本，提高了數據準確性，從而促進了其在臨床和研究領域的應用。

關鍵成長要素包括慢性病發病率上升、對標靶治療的需求不斷成長以及政府推行精準醫療計劃。製藥公司正在利用藥理基因組學知識來最佳化藥物研發並最大限度地減少藥物不良反應。此外，臨床試驗的擴展和基因組研究投資的增加正在推動已開發國家和開發中國家的市場成長。

隨著人工智慧驅動的分析和次世代定序平台革新基因組解讀方式，未來前景依然十分光明。將藥物基因組學整合到電子健康記錄中，能夠簡化臨床決策流程。隨著醫保報銷機制的完善和監管流程的日益清晰，預計未來幾年，藥物基因組學在常規臨床實踐中的更廣泛應用將釋放巨大的成長潛力。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球藥物遺傳學技術市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 神經系統疾病
• 心血管疾病
• 免疫疾病
• 感染疾病
• 其他

第5章 全球藥物基因學技術市場：依技術分類

• 市場分析、洞察與預測
• PCR
• 原位雜合反應
• 免疫組織化學
• 定序
• 其他

第6章 全球藥物基因技術市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • QIAGEN
  • GE HealthCare
  • Agilent Technologies Inc
  • FA¢a,A¯Hoffmann La Roche Ltd
  • Foundation Medicine Inc
  • Thermo Fisher Scientific Inc
  • Oxford Nanopore Technologies Plc
  • Twist Bioscience
  • Leica Biosystems Nussloch GmbH
  • Pfizer Inc
  • Abbott Laboratories

The Pharmacogenomics Technology Market size is expected to reach USD 18.45 Billion in 2034 from USD 8.77 Billion (2025) growing at a CAGR of 8.62% during 2026-2034.

The Global Pharmacogenomics Technology Market is witnessing rapid growth as personalized medicine becomes central to modern healthcare strategies. Increasing awareness about genetic variability in drug response is encouraging healthcare systems to integrate genomic testing into routine treatment protocols. Advances in sequencing technologies and bioinformatics tools have reduced testing costs and improved data accuracy, strengthening adoption across clinical and research settings.

Key drivers include rising incidences of chronic diseases, growing demand for targeted therapies, and government initiatives promoting precision medicine programs. Pharmaceutical companies are leveraging pharmacogenomic insights to optimize drug development and minimize adverse drug reactions. Additionally, expanding clinical trials and investments in genomic research are reinforcing market expansion across developed and developing economies.

Future prospects remain highly promising as AI-driven analytics and next-generation sequencing platforms reshape genomic interpretation. Integration of pharmacogenomics into electronic health records will streamline clinical decision-making. As reimbursement frameworks improve and regulatory pathways become clearer, broader implementation in routine clinical practice is expected to unlock significant growth potential in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

COMPANIES PROFILED

• QIAGEN, GE HealthCare, Agilent Technologies Inc, FHoffmann La Roche Ltd, Foundation Medicine Inc, Thermo Fisher Scientific Inc, Oxford Nanopore Technologies plc, Twist Bioscience, Leica Biosystems Nussloch GmbH, Pfizer Inc, Abbott Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Area
• 4.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In-situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunohistochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapeutic Area
  • 6.2.2 By Technology
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapeutic Area
  • 6.3.2 By Technology
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapeutic Area
  • 6.4.2 By Technology
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapeutic Area
  • 6.5.2 By Technology
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapeutic Area
  • 6.6.2 By Technology
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 QIAGEN
  • 8.2.2 GE HealthCare
  • 8.2.3 Agilent Technologies Inc
  • 8.2.4 F.A¢a,A¯Hoffmann La Roche Ltd
  • 8.2.5 Foundation Medicine Inc
  • 8.2.6 Thermo Fisher Scientific Inc
  • 8.2.7 Oxford Nanopore Technologies Plc
  • 8.2.8 Twist Bioscience
  • 8.2.9 Leica Biosystems Nussloch GmbH
  • 8.2.10 Pfizer Inc
  • 8.2.11 Abbott Laboratories